|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Germany
Espicom Business Intelligence Ltd, Sep 2009, Pages: 90
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
Germany represents the largest pharmaceutical market in Europe, at an estimated 46.2 billion euros (US$61.7 billion) in 2009. This equates to US$745 per capita and 18.7% of total health expenditure. The retail prescription market is estimated at 33.4 billion euros, equal to 72.2% of the total.
Pharmaceutical expenditure is largely funded through the GKV, or public health insurance system. GKV drug expenditure amounted to 24.8 billion euros in 2007, equal to 80.8% of the retail prescription market. The GKV is composed of a number of different public insurers, of which the largest is the AOK.
Germany has been grappling with ways to rein in its healthcare expenditure since the 1990s. In the pharmaceutical field this is ongoing and has taken various forms: stricter reimbursement critera, reference pricing and negotiation of discount contracts with generic manufacturers. The net effect of all this is a reduction in GKV prices of 1.6% between January 2007 and September 2008.
Germany has a very strong tradition of pharmaceutical R&D, dating back at least as far as Bayer’s development of Aspirin in 1897. The manufacturing sector has lost ground in the face of US competition, but retains a handful of major multinational companies, headed by Bayer Schering, Boehringer Ingelheim and Merck Serono. Sanofi-Aventis, though based in France, retains significant capacity in Germany. Behind these are a vast number of smaller producers, biotech developers and generic manufacturers. As a result, the country is one of the largest drug exporters in the world, with shipments valued at US$51.6 billion in 2007.
Germany has the largest generic market in Europe, both in terms of size and the level of generic penetration (36.5% in 2007). Obtaining even greater value through more widespread use of generics remains a key objective of the government, particularly with regard to boosting their use in place of older patent-expired branded medicines. The country is also the preferred initial launch market for biosimilar products in Europe, from companies such as Hospira, Sandoz and Stada Arzneimittel.
Customers who bought this item also bought
The Medical Device Market: Germany
Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008
The World Generic Market Report 2008
Stada Arzneimittel Generics Company Intelligence Report
Pharmaceutical Pricing and Reimbursement in China
Emerging Generic Drug Markets in Europe
Pharmaceutical Pricing and Reimbursement in India
European Generic Drug Market Potential
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Second Quarter of 2009
Pharmaceutical Pricing and Reimbursement in France, 2008
|
|
|
|
